Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how ...

Cash management is critical for pharmaceutical companies: The ability to fund drug innovation can make the difference between ...

If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks ...

Fintel reports that on January 7, 2026, UBS upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral to Buy.

Bristol Myers Squibb (BMY) is undervalued and poised for growth, with strong dividends and robust financials. Read here for ...

Bristol Myers Squibb has a robust pipeline with plenty of active programs, and its outlook for the next decade remains strong ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap ...

Bristol-Myers Squibb Company is rated a Buy with solid rebound and robust free cash flow margins. Learn more about BMY stock here.

Bristol Myers Squibb’s (NYSE: BMY) financial results haven’t been great lately. Its third-quarter revenue of $12.2 billion was an increase of only 3% year over year. To make matters worse, over the ...

Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or ...

Deep-pocketed investors have adopted a bullish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...